Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark F Brady

Showing results (31-40 of 64) with videos related to

Pageof 7
Sort By:
Gynecologic Oncology|July 25, 2006
Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group studyJeffrey Bell, Mark F Brady, Robert C Young, et al.
The New England Journal of Medicine|December 14, 2004
Secondary surgical cytoreduction for advanced ovarian carcinomaPeter G Rose, Stacy Nerenstone, Mark F Brady, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2003
Adjuvant treatment for early ovarian cancer: a randomized phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin--a gynecologic oncology group studyRobert C Young, Mark F Brady, Roberta K Nieberg, et al.
Gynecologic Oncology|September 8, 2007
A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterusAaron H Wolfson, Mark F Brady, Thomas Rocereto, et al.
Gynecologic Oncology|May 3, 2011
A randomized phase III trial of IV carboplatin and paclitaxel × 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: a Gynecologic Oncology Group StudyRobert S Mannel, Mark F Brady, Elise C Kohn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 2003
Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup studyGeorge A Omura, Mark F Brady, Katherine Y Look, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 2, 2007
Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group StudyDavid R Spriggs, Mark F Brady, Luis Vaccarello, et al.
Journal of the National Cancer Institute|October 24, 2017
Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker AnalysesCarlos Bais, Barbara Mueller, Mark F Brady, et al.
Gynecologic Oncology|September 24, 2004
Analysis of CHEK2 gene for ovarian cancer susceptibilityBora E Baysal, Julie A DeLoia, Joan E Willett-Brozick, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|August 5, 2010
Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancerHelen J Mackay, Mark F Brady, Amit M Oza, et al.
Pageof 7

Showing results (31-40 of 64) with videos related to

Sort By:
Pageof 7
Gynecologic Oncology|July 25, 2006
Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group studyJeffrey Bell, Mark F Brady, Robert C Young, et al.
The New England Journal of Medicine|December 14, 2004
Secondary surgical cytoreduction for advanced ovarian carcinomaPeter G Rose, Stacy Nerenstone, Mark F Brady, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2003
Adjuvant treatment for early ovarian cancer: a randomized phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin--a gynecologic oncology group studyRobert C Young, Mark F Brady, Roberta K Nieberg, et al.
Gynecologic Oncology|September 8, 2007
A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterusAaron H Wolfson, Mark F Brady, Thomas Rocereto, et al.
Gynecologic Oncology|May 3, 2011
A randomized phase III trial of IV carboplatin and paclitaxel × 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: a Gynecologic Oncology Group StudyRobert S Mannel, Mark F Brady, Elise C Kohn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 2003
Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup studyGeorge A Omura, Mark F Brady, Katherine Y Look, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 2, 2007
Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group StudyDavid R Spriggs, Mark F Brady, Luis Vaccarello, et al.
Journal of the National Cancer Institute|October 24, 2017
Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker AnalysesCarlos Bais, Barbara Mueller, Mark F Brady, et al.
Gynecologic Oncology|September 24, 2004
Analysis of CHEK2 gene for ovarian cancer susceptibilityBora E Baysal, Julie A DeLoia, Joan E Willett-Brozick, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|August 5, 2010
Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancerHelen J Mackay, Mark F Brady, Amit M Oza, et al.
Pageof 7